Examples of options we may consider after evaluating you; not everyone qualifies; some uses may be off-label; risks/contraindications will be reviewed before prescribing.

Many primary care providers default to basic antihistamines like diphenhydramine or doxylamine, or prescribe GABAergic medications (benzodiazepines, “Z-drugs” like zolpidem/Ambien, eszopiclone/Lunesta) that can provide short-term relief but come with significant long-term concerns. We take a more nuanced, neurobiologically-informed approach to sleep medication selection.

Antiserotonergic agents with antihistamine properties

We generally favor medications that combine serotonin antagonism with H1 antihistamine effects, as these can be particularly helpful for sleep initiation and maintenance in the right patient.

Mirtazapine and trazodone work by blocking specific serotonin receptors (5-HT2 family receptors, including 5-HT2A/5-HT2C) while also providing sedating antihistamine effects, promoting both sleep initiation and maintenance.^3-5

Compared with GABAergic hypnotics, these options do not rely on GABA-A over-activation to create sleep, which is one reason tolerance and rebound issues are often less pronounced (though side effects can still happen and individual responses vary).^3-7

Mirtazapine is generally the more potent/sedating of the two, while trazodone is weaker, but often less associated with weight gain and can be easier to tolerate the next day (still patient-dependent).^3-5,23

GABAergic medications (Benzodiazepines & Z-drugs)

While benzodiazepines (temazepam, triazolam) and Z-drugs (zolpidem, eszopiclone, zaleplon) can be effective initially, they carry substantial risks: rapid tolerance development (sometimes within days to weeks), rebound insomnia upon discontinuation, dependence potential, cognitive/psychomotor impairment, increased fall and fracture risk (especially in older adults), and disruption of natural sleep architecture.^1,2,6-9

These agents essentially force sedation rather than facilitating natural sleep processes, with over-activation of inhibitory signaling contributing to rapid tolerance in many patients.^6,7

Traditional antihistamines (Hydroxyzine)

Over-the-counter options like diphenhydramine (Benadryl) or doxylamine may help occasionally, but tolerance develops quickly and sleep benefits tend to fade with repeated use.²¹

Most also act as “anticholinergics,” which contributes to next-day grogginess, and can worsen confusion/cognitive function in older adults or contribute to overall anticholinergic burden.²

For patients who prefer antihistamines, we lead with hydroxyzine, which has lower anticholinergic activity than diphenhydramine in some pharmacology models (though not zero).^10,11

DORAs (Dual Orexin Receptor Antagonists)

These represent a fundamentally different approach that many PCPs are unfamiliar with.

Medications like Quviviq (daridorexant) and Belsomra (suvorexant) work by blocking orexin, a neurotransmitter system that promotes wakefulness. Rather than forcing sleep through broad CNS sedation, they dampen the “wake signal,” which can allow sleep to unfold more naturally.^12,13

This approach tends to preserve overall sleep-stage balance better than many GABAergic hypnotics, including REM and deep sleep stages (as shown in detailed EEG/sleep-architecture analyses with daridorexant).^15,22

DORAs generally have less of a tolerance/rebound pattern than benzodiazepines, and they have clinical trial data supporting longer-term use in appropriate patients, but they still require careful selection and monitoring for impairment and next-day effects.^6,12,22

Quviviq in particular has favorable pharmacokinetics with less next-morning residual effect risk than older DORAs for many patients: its terminal half-life is shorter than suvorexant (Belsomra) and lemborexant (Dayvigo), which can matter for morning grogginess in real life.^12-14

Alpha-2 adrenergic agonists (a2 agonists)

Alpha-2 adrenergic agonists such as clonidine can be helpful when insomnia is driven by “hyperarousal,” especially when the problem is less about sleepiness and more about your body refusing to downshift: racing heart, sweating, feeling on edge, or persistent mental looping/ruminations.^16,18

Clonidine reduces sympathetic outflow from the central nervous system and lowers heart rate and blood pressure, which is exactly why it can be calming for patients whose insomnia feels physical rather than purely cognitive.^16,24

From a practical standpoint, immediate-release clonidine has a plasma half-life that typically falls in the 12 to 16 hour range, making it relatively shorter acting and (for many patients) more sedating, which can be useful at bedtime when the goal is night-time calming rather than all-day symptom coverage.²⁴

They may be especially helpful for patients with ADHD (including those whose sleep is disrupted by baseline restlessness or stimulant-related sleep difficulty), and clonidine has an FDA-approved ADHD formulation (extended-release clonidine) that reflects how commonly this pathway is used in ADHD care.^16,18

Key risks we review for clonidine include low blood pressure, dizziness/syncope, bradycardia, excessive sedation, and rebound effects if it is stopped abruptly, so dosing and discontinuation require planning.¹⁶

Even when insomnia is more “general,” clonidine can still be worth considering for some patients, particularly when anxiety-adjacent physical tension is prominent, but it is not a one-size-fits-all choice.

Why we care about obstructive sleep apnea (OSA) testing

If you have maintenance insomnia (frequent awakenings), obesity, high blood pressure, loud snoring, morning headaches, or sleep that feels non-restorative even when you technically get “enough hours,” we take obstructive sleep apnea (OSA) seriously and often recommend testing rather than guessing.^19,20

OSA commonly fragments sleep (which can look like insomnia) and can worsen blood pressure and cardiometabolic risk over time, so identifying it can change the entire treatment plan.^19,20 Moreso, trying to treat OSA related insomnia with meds alone may be ineffective.

Testing can be done with an in-lab polysomnogram or, in appropriate patients, a home sleep apnea test (which we can refer for and manage), consistent with American Academy of Sleep Medicine diagnostic guidance.¹⁹

It also matters because some sedating medications can worsen breathing-related issues in vulnerable patients, so hypnotic selection should be made with sleep-disordered breathing risk in mind.^7,19

How we choose

We select sleep medications based on your specific insomnia pattern (sleep onset vs. maintenance), comorbid conditions (depression, anxiety, pain), age, and medication history, not simply what’s most familiar or easiest to prescribe.

References

1. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(2):307-349.

2. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081.

3. RemeronSolTab (mirtazapine) [package insert]. U.S. Food and Drug Administration. Revised March 2020.

4. Trazodone hydrochloride [package insert]. U.S. Food and Drug Administration. Revised January 2014.

5. Jaffer KY, Chang T, Vanle B, Dang J, Steiner AJ, Loera N, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14(7-8):24-34.

6. Soyka M. Long-term use of benzodiazepines in chronic insomnia: a European perspective. Front Psychiatry. 2023;14:1212028.

7. Ambien (zolpidem tartrate) [package insert]. U.S. Food and Drug Administration. Revised February 2022.

8. Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults: a systematic review and meta-analysis. Age Ageing. 2018;47(2):201-208.

9. Schifano F, Chiappini S, Corkery JM, Guirguis A. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019;22(4):270-277.

10. Orzechowski RF, Currie DS, Valancius CA. Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models. Eur J Pharmacol. 2005;506(3):257-264.

11. Hydroxyzine hydrochloride [package insert]. U.S. Food and Drug Administration. Revised 2014.

12. QUVIVIQ (daridorexant) [package insert]. U.S. Food and Drug Administration. Revised September 2024.

13. Belsomra (suvorexant) [package insert]. U.S. Food and Drug Administration. Revised 2020.

14. Dayvigo (lemborexant) [package insert]. U.S. Food and Drug Administration. Revised 2025.

15. Di Marco T, et al. Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies. Sleep. 2024;47(11):zsae098.

16. Kapvay (clonidine hydrochloride) extended-release tablets [package insert]. U.S. Food and Drug Administration. Revised 2020.

17. Intuniv (guanfacine) extended-release tablets [package insert]. U.S. Food and Drug Administration. Revised 2013.

18. Stein MA, Weiss M, Hlavaty L. ADHD treatments, sleep, and sleep problems: complex associations. Neurotherapeutics. 2012;9(3):509-517.

19. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017;13(3):479-504.

20. Merck Manual Professional Version. Obstructive sleep apnea. Accessed January 18, 2026.

21. Richardson GS, Roehrs TA, Rosenthal L, Koshorek G, Roth T. Tolerance to the sedative effects of H1 antihistamines. J Clin Psychopharmacol. 2002;22(5):511-515.

22. Kron JO-ZJ, Keenan RJ, Hoyer D, Jacobson LH. Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease. Annu Rev Pharmacol Toxicol. 2024;64:359-386.

23. Sasada K, Iwamoto K, Kawano N, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol. 2013;28(3):281-286.

24. Catapres (clonidine hydrochloride, USP) tablets [package insert]. U.S. Food and Drug Administration. 2009.